Gaithersburg, Maryland – November 21, 2018: MaxCyte announced today that Doug Doerfler, Chief Executive Officer, will present a company overview at the Piper Jaffray 30th Annual Healthcare Conference on Wednesday, November 28, 2018, at 1:10 p.m. ET in New York City.
Released : November 21, 2018 07:00 RNS Number : 9686H MaxCyte, Inc. 21 November 2018 NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES , TO ANY US PERSON OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
Released : November 20, 2018 07:00 RNS Number : 8340H MaxCyte, Inc. 20 November 2018 SCHEDULE 6 AIM BLOCK ADMISSION SIX MONTHLY RETURN / TOTAL VOTING RIGHTS Please ensure the entries on this return are typed a. Name of company MaxCyte, Inc. b.
Released : November 16, 2018 07:00 RNS Number : 5521H MaxCyte, Inc. 16 November 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte to host webinar: "Non-viral cell engineering: enabling a therapeutic revolution" Gaithersburg, Maryland - 16 November 2018: MaxCyte
Released : November 14, 2018 07:00 RNS Number : 2611H MaxCyte, Inc. 14 November 2018 MaxCyte, Inc. ("MaxCyte") Precision BioSciences and MaxCyte Enter into Clinical and Commercial License Agreement Precision BioSciences gains rights to MaxCyte's cell engineering technology to develop
Released : November 12, 2018 07:00 RNS Number : 9788G MaxCyte, Inc. 12 November 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Announces Research Agreement with Kite, a Gilead Company Gaithersburg, Maryland - 12 November 2018: MaxCyte (LSE: MXCT, MXCR), the global
Released : November 09, 2018 07:00 RNS Number : 8499G MaxCyte, Inc. 09 November 2018 MaxCyte, Inc. ("MaxCyte") CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement
Released : October 31, 2018 16:25 RNS Number : 9281F MaxCyte, Inc. 31 October 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Result of AGM Gaithersburg, MD - 31 October 2018 : MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company, announces that at its
Gaithersburg, Maryland – October 30, 2018: MaxCyte announced today that Debra K. Bowes , Chief Business Officer, CARMA Cell Therapy, will present “Novel mRNA-based Autologous CAR Therapies in Oncology” at the 24th Annual International Partnering Conference BIO-EUROPE.
Released : October 10, 2018 07:00 RNS Number : 4884D MaxCyte, Inc. 10 October 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Commences Dosing in First Clinical Trial in Solid Tumours First patient dosed in Phase I clinical study to evaluate MaxCyte's lead CAR therapeutic in
